Design, synthesis, and radioprotection activity evaluation of 1H-1,2,3-triazole derivatives as TLR2/1 small molecule agonists
Bioorganic & Medicinal Chemistry Letters · 2026-08 · 137 · 130657
DOI: 10.1016/j.bmcl.2026.130657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2026-08. Verfasst von Hao Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China; Beijing Institute of Radiation Medicine, Beijing, 100850, PR Ch…. Hauptthemen laut MEDLINE: Toll-Like Receptor 2, Radiation-Protective Agents, Triazoles, Toll-Like Receptor 1. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Toll-like receptors (TLRs), a family of pattern recognition receptors of the innate immune system, have been shown to exert radioprotective effects by activating the NF-κB signaling pathway. In this context, we designed and synthesized a series of novel TLR2/1 small molecule agonists, 1H-1,2,3-triazole derivatives, to evaluate their radioprotective activity, with compound H9 exhibiting the most potent radiation-protective effect.H9 showed significant radioprotective effects in mice irradiated with 8.5 Gy of 60Co γ rays. The survival rates of the 80 mg/kg and 60 mg/kg H9-treated groups were both 100%. Furthermore, H9 can accelerate the recovery of peripheral blood cells in irradiated mice. The ELISA experiment showed that the levels of the antiradiation cytokine biomarker G-CSF were significantly increased in the serum of irradiated mice after treatment with H9. In human TLR2 and TLR1 transiently cotransfected HEK 293 T cells., H9 exhibits significant TLR2/1 agonist activity. Immunoprecipitation and cellular thermal shift assays (CETSA) confirmed that H9 targets the TLR2/1 rather than TLR2/6 heterodimeric complex. Summary: We demonstrated that H9 is a novel TLR2/1 agonist with significant efficacy in acute radiation protection, indicating that TLR2/1 small molecule agonists hold broad promise for applications in acute radioprotection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China; Beijing Institute of Radiation Medicine, Beijing, 100850, PR China.
- Beijing Institute of Radiation Medicine, Beijing, 100850, PR China.
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.
- Beijing Institute of Radiation Medicine, Beijing, 100850, PR China. Electronic address: liusc118@sohu.com.
- Beijing Institute of Radiation Medicine, Beijing, 100850, PR China. Electronic address: zhangshouguo1409@sina.com.
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China; Beijing Institute of Radiation Medicine, Beijing, 100850, PR China. Electronic address: wanglin@bmi.ac.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, H., Liu, X., Zheng, W., Xu, J., Liu, S., Zhang, S., Wang, L., & Peng, T. (2026). Design, synthesis, and radioprotection activity evaluation of 1H-1,2,3-triazole derivatives as TLR2/1 small molecule agonists. Bioorganic & Medicinal Chemistry Letters, 137, 130657. https://doi.org/10.1016/j.bmcl.2026.130657
Vancouver
Wang H, Liu X, Zheng W, Xu J, Liu S, Zhang S, et al. Design, synthesis, and radioprotection activity evaluation of 1H-1,2,3-triazole derivatives as TLR2/1 small molecule agonists. Bioorganic & Medicinal Chemistry Letters. 2026;137:130657. doi:10.1016/j.bmcl.2026.130657
BibTeX
@article{Wang2026,
author = {Wang, Hao and Liu, Xinru and Zheng, Wenteng and Xu, Jing and Liu, Shuchen and Zhang, Shouguo and Wang, Lin and Peng, Tao},
title = {Design, synthesis, and radioprotection activity evaluation of 1H-1,2,3-triazole derivatives as TLR2/1 small molecule agonists},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2026},
volume = {137},
pages = {130657},
doi = {10.1016/j.bmcl.2026.130657}
}
EUVIMED